Literature DB >> 26743220

Developmental changes of MPA exposure in children.

Elisa C Yoo1, Ana Catalina Alvarez-Elías1,2, Ekaterina Kirilova Todorova1, Guido Filler3,4,5,6.   

Abstract

BACKGROUND: Developmental changes (ontogeny) of drug disposition of Mycophenolate mofetil (MMF) have been understudied.
METHODS: The charts of 37 pediatric renal transplant recipients (median age 7.3 years, median follow-up 7.8 (IQR 6.6, 14.3 years) who had regular mycophenolic acid (MPA) trough level monitoring in combination with tacrolimus (n = 31) or sirolimus (n = 6) therapy were analyzed retrospectively for their dose-normalized MPA exposure, steroid dose, albumin, hematocrit, and cystatin C estimated glomerular filtration rate (eGFR). Using appropriate univariate and multivariate methods, we determined whether MPA exposure was age dependent when controlling for the confounders.
RESULTS: Dose-normalized MPA trough levels could be calculated in 2,128 (median 45/patient) instances. Spearman rank correlation analysis revealed that age correlated with dose-normalized MPA trough level for both body weight and body surface area, as well as serum albumin, hematocrit, steroid dose, and eGFR. In the multivariate analysis, serum albumin and steroid dose were not significant, and hematocrit only being significant when the youngest group of patients < 6 years of age was compared. eGFR was the most important confounder, but age dependency remained significant when controlling for all confounders.
CONCLUSIONS: Small children are at a significantly greater risk for low MPA trough levels than adolescents, highlighting the need for pharmacokinetic monitoring of MPA.

Entities:  

Keywords:  Kidney transplantation; Mycophenolate mofetil; Mycophenolic acid trough levels; Ontogeny; Pediatric; Therapeutic drug monitoring

Mesh:

Substances:

Year:  2016        PMID: 26743220     DOI: 10.1007/s00467-015-3303-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  38 in total

1.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

2.  Pharmacodynamic monitoring of mycophenolate mofetil.

Authors:  K Budde; P Glander; S Bauer; K Braun; J Waiser; L Fritsche; I Mai; I Roots; H H Neumayer
Journal:  Clin Chem Lab Med       Date:  2000-11       Impact factor: 3.694

3.  Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.

Authors:  Wei Zhao; Valéry Elie; Véronique Baudouin; Albert Bensman; Jean Luc André; Karine Brochard; Françoise Broux; Mathilde Cailliez; Chantal Loirat; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2010-04       Impact factor: 4.335

4.  Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation.

Authors:  G Filler; J Foster; R Berard; I Mai; N Lepage
Journal:  Transplant Proc       Date:  2004-06       Impact factor: 1.066

5.  Similar MPA exposure on modified release and regular tacrolimus.

Authors:  Guido Filler; Alexander A Vinks; Shih-Han S Huang; Anthony Jevnikar; Norman Muirhead
Journal:  Ther Drug Monit       Date:  2014-06       Impact factor: 3.681

Review 6.  Clinical pharmacokinetics of mycophenolate mofetil.

Authors:  R E Bullingham; A J Nicholls; B R Kamm
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

7.  Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy.

Authors:  Guido Filler
Journal:  Transpl Int       Date:  2004-01-29       Impact factor: 3.782

8.  Long-term pharmacokinetics of mycophenolic acid in pediatric renal transplant recipients over 3 years posttransplant.

Authors:  Lutz T Weber; Britta Hoecker; Victor W Armstrong; Michael Oellerich; Burkhard Tönshoff
Journal:  Ther Drug Monit       Date:  2008-10       Impact factor: 3.681

9.  Complications of chronic kidney disease in children post-renal transplantation - a single center experience.

Authors:  Janusz Feber; Hubert Wong; Pavel Geier; Bushra Chaudry; Guido Filler
Journal:  Pediatr Transplant       Date:  2008-02

10.  UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients.

Authors:  Tsuyoshi Fukuda; Jens Goebel; Shareen Cox; Denise Maseck; Kejian Zhang; Joseph R Sherbotie; Eileen N Ellis; Laura P James; Robert M Ward; Alexander A Vinks
Journal:  Ther Drug Monit       Date:  2012-12       Impact factor: 3.681

View more
  6 in total

1.  Ten-year treatment with mycophenolate mofetil using therapeutic drug monitoring for childhood-onset lupus nephritis in Japan.

Authors:  Shuichiro Fujinaga; Tomohiko Nishino
Journal:  Pediatr Nephrol       Date:  2016-10-13       Impact factor: 3.714

2.  Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients.

Authors:  Zi-Cheng Yu; Pei-Jun Zhou; Xiang-Hui Wang; Bressolle Françoise; Da Xu; Wei-Xia Zhang; Bing Chen
Journal:  Acta Pharmacol Sin       Date:  2017-08-24       Impact factor: 6.150

3.  Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.

Authors:  Shuichiro Fujinaga; Daishi Hirano; Tomohiko Nishino; Chisato Umeda; Yoshitaka Watanabe; Mayu Nakagawa
Journal:  Pediatr Nephrol       Date:  2019-08-21       Impact factor: 3.714

4.  Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: Influence of genes and drugs.

Authors:  Charles D Varnell; Tsuyoshi Fukuda; Cassie L Kirby; Lisa J Martin; Barry L Warshaw; Hiren P Patel; Deepa H Chand; Gina-Marie Barletta; Scott K Van Why; Rene G VanDeVoorde; Donald J Weaver; Amy Wilson; Priya S Verghese; Alexander A Vinks; Larry A Greenbaum; Jens Goebel; David K Hooper
Journal:  Pediatr Transplant       Date:  2017-09-04

5.  Does Vitamin D Affect Chronic Renal Allograft Function in Pediatric Transplant Patients?

Authors:  Brooke Wile; Elisa Yoo; Ana Catalina Alvarez Elias; Lakshmimathy Subramanian; Kathryn Eager; Ajay Parkesh Sharma; Guido Filler
Journal:  Ann Transplant       Date:  2018-04-17       Impact factor: 1.530

Review 6.  Recent Advances in Therapeutic Drug Monitoring of Voriconazole, Mycophenolic Acid, and Vancomycin: A Literature Review of Pediatric Studies.

Authors:  Matylda Resztak; Joanna Sobiak; Andrzej Czyrski
Journal:  Pharmaceutics       Date:  2021-11-23       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.